243 related articles for article (PubMed ID: 21937681)
21. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast growth factor receptor 1 (FGFR1) tyrosine phosphorylation regulates binding of FGFR substrate 2alpha (FRS2alpha) but not FRS2 to the receptor.
Zhang Y; McKeehan K; Lin Y; Zhang J; Wang F
Mol Endocrinol; 2008 Jan; 22(1):167-75. PubMed ID: 17901128
[TBL] [Abstract][Full Text] [Related]
23. Development of ZMYM2-FGFR1 driven AML in human CD34+ cells in immunocompromised mice.
Ren M; Qin H; Wu Q; Savage NM; George TI; Cowell JK
Int J Cancer; 2016 Aug; 139(4):836-40. PubMed ID: 27005999
[TBL] [Abstract][Full Text] [Related]
24. Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase.
Ren M; Li X; Cowell JK
Blood; 2009 Aug; 114(8):1576-84. PubMed ID: 19506298
[TBL] [Abstract][Full Text] [Related]
25. FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome.
Xiao S; Nalabolu SR; Aster JC; Ma J; Abruzzo L; Jaffe ES; Stone R; Weissman SM; Hudson TJ; Fletcher JA
Nat Genet; 1998 Jan; 18(1):84-7. PubMed ID: 9425908
[TBL] [Abstract][Full Text] [Related]
26. 14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells.
Dong S; Kang S; Gu TL; Kardar S; Fu H; Lonial S; Khoury HJ; Khuri F; Chen J
Blood; 2007 Jul; 110(1):360-9. PubMed ID: 17389761
[TBL] [Abstract][Full Text] [Related]
27. SRC signaling is crucial in the growth of synovial sarcoma cells.
Michels S; Trautmann M; Sievers E; Kindler D; Huss S; Renner M; Friedrichs N; Kirfel J; Steiner S; Endl E; Wurst P; Heukamp L; Penzel R; Larsson O; Kawai A; Tanaka S; Sonobe H; Schirmacher P; Mechtersheimer G; Wardelmann E; Büttner R; Hartmann W
Cancer Res; 2013 Apr; 73(8):2518-28. PubMed ID: 23580575
[TBL] [Abstract][Full Text] [Related]
28. Functional characterization, localization, and inhibitor sensitivity of the TPR-FGFR1 fusion in 8p11 myeloproliferative syndrome.
Malli T; Buxhofer-Ausch V; Rammer M; Erdel M; Kranewitter W; Rumpold H; Marschon R; Deutschbauer S; Simonitsch-Klupp I; Valent P; Muellner-Ammer K; Sebesta C; Birkner T; Webersinke G
Genes Chromosomes Cancer; 2016 Jan; 55(1):60-8. PubMed ID: 26391436
[TBL] [Abstract][Full Text] [Related]
29. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu Y; Karaca M; Zhang Z; Gioeli D; Earp HS; Whang YE
Oncogene; 2010 Jun; 29(22):3208-16. PubMed ID: 20383201
[TBL] [Abstract][Full Text] [Related]
30. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
31. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
32. Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib.
Landberg N; Dreimane A; Rissler M; Billström R; Ågerstam H
Eur J Haematol; 2017 Nov; 99(5):442-448. PubMed ID: 28881484
[TBL] [Abstract][Full Text] [Related]
33. IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies.
Cai B; Liu Y; Chong Y; Zhang H; Matsunaga A; Fang X; Pacholczyk R; Zhou G; Cowell JK; Hu T
Mol Cancer; 2021 Dec; 20(1):165. PubMed ID: 34906138
[TBL] [Abstract][Full Text] [Related]
34. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
35. A case of 8p11 myeloproliferative syndrome with BCR-FGFR1 gene fusion presenting with trilineage acute leukemia/lymphoma, successfully treated by cord blood transplantation.
Morishige S; Oku E; Takata Y; Kimura Y; Arakawa F; Seki R; Imamura R; Osaki K; Hashiguchi M; Yakushiji K; Mizuno S; Yoshimoto K; Nagafuji K; Ohshima K; Okamura T
Acta Haematol; 2013; 129(2):83-9. PubMed ID: 23171834
[TBL] [Abstract][Full Text] [Related]
36. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
37. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
Congleton J; MacDonald R; Yen A
Leukemia; 2012 Jun; 26(6):1180-8. PubMed ID: 22182854
[TBL] [Abstract][Full Text] [Related]
38. The driver of malignancy in KG-1a leukemic cells, FGFR1OP2-FGFR1, encodes an HSP90 addicted oncoprotein.
Jin Y; Zhen Y; Haugsten EM; Wiedlocha A
Cell Signal; 2011 Nov; 23(11):1758-66. PubMed ID: 21745565
[TBL] [Abstract][Full Text] [Related]
39. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
40. Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.
Ke J; Chelvarajan RL; Sindhava V; Robertson DA; Lekakis L; Jennings CD; Bondada S
Mol Cancer; 2009 Dec; 8():132. PubMed ID: 20043832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]